LAKE FOREST, Ill. — Akorn, a leading specialty pharmaceutical company, Monday announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (Augmented), 0.05%. The product is manufactured at Akorn’s Amityville, N.Y. manufacturing facility.
According to IQVIA, U.S. sales of betamethasone dipropionate lotion (Augmented), 0.05% were approximately $10 million for the twelve months ended August 2019.Betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.
